Show simple item record

dc.contributor.authorZormpas-Petridis, K
dc.contributor.authorJerome, NP
dc.contributor.authorBlackledge, MD
dc.contributor.authorCarceller, F
dc.contributor.authorPoon, E
dc.contributor.authorClarke, M
dc.contributor.authorMcErlean, CM
dc.contributor.authorBarone, G
dc.contributor.authorKoers, A
dc.contributor.authorVaidya, SJ
dc.contributor.authorMarshall, LV
dc.contributor.authorPearson, ADJ
dc.contributor.authorMoreno, L
dc.contributor.authorAnderson, J
dc.contributor.authorSebire, N
dc.contributor.authorMcHugh, K
dc.contributor.authorKoh, D-M
dc.contributor.authorYuan, Y
dc.contributor.authorChesler, L
dc.contributor.authorRobinson, SP
dc.contributor.authorJamin, Y
dc.date.accessioned2019-03-18T09:56:16Z
dc.date.issued2019-06
dc.identifier.citationCancer research, 2019, 79 (11), pp. 2978 - 2991
dc.identifier.issn0008-5472
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3153
dc.identifier.eissn1538-7445
dc.identifier.doi10.1158/0008-5472.can-18-3412
dc.description.abstractChildhood neuroblastoma is a hypervascular tumor of neural origin, for which antiangiogenic drugs are currently being evaluated; however, predictive biomarkers of treatment response, crucial for successful delivery of precision therapeutics, are lacking. We describe an MRI-pathologic cross-correlative approach using intrinsic susceptibility (IS) and susceptibility contrast (SC) MRI to noninvasively map the vascular phenotype in neuroblastoma Th-MYCN transgenic mice treated with the vascular endothelial growth factor receptor inhibitor cediranib. We showed that the transverse MRI relaxation rate R 2 * (second -1 ) and fractional blood volume ( f BV, %) were sensitive imaging biomarkers of hemorrhage and vascular density, respectively, and were also predictive biomarkers of response to cediranib. Comparison with MRI and pathology from patients with MYCN-amplified neuroblastoma confirmed the high degree to which the Th-MYCN model vascular phenotype recapitulated that of the clinical phenotype, thereby supporting further evaluation of IS- and SC-MRI in the clinic. This study reinforces the potential role of functional MRI in delivering precision medicine to children with neuroblastoma. SIGNIFICANCE: This study shows that functional MRI predicts response to vascular-targeted therapy in a genetically engineered murine model of neuroblastoma.
dc.formatPrint-Electronic
dc.format.extent2978 - 2991
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectAnimals
dc.subjectMice, Transgenic
dc.subjectHumans
dc.subjectNeuroblastoma
dc.subjectNeoplasms, Experimental
dc.subjectQuinazolines
dc.subjectAngiogenesis Inhibitors
dc.subjectProtein Kinase Inhibitors
dc.subjectContrast Media
dc.subjectMagnetic Resonance Imaging
dc.subjectTreatment Outcome
dc.subjectProspective Studies
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectInfant
dc.subjectFemale
dc.subjectMale
dc.subjectN-Myc Proto-Oncogene Protein
dc.titleMRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment.
dc.typeJournal Article
dcterms.dateAccepted2019-03-12
rioxxterms.versionofrecord10.1158/0008-5472.can-18-3412
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2019-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCancer research
pubs.issue11
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Paediatric Solid Tumour Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Paediatric Solid Tumour Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Computational Pathology & Integrated Genomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Paediatric Solid Tumour Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Computational Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Pre-Clinical MRI
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/16/17 Starting Cohort
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Paediatric Solid Tumour Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Paediatric Solid Tumour Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Computational Pathology & Integrated Genomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Paediatric Solid Tumour Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Computational Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Pre-Clinical MRI
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/16/17 Starting Cohort
pubs.publication-statusPublished
pubs.volume79
pubs.embargo.terms12 months
icr.researchteamComputational Pathology & Integrated Genomicsen_US
icr.researchteamPaediatric Solid Tumour Biology and Therapeuticsen_US
icr.researchteamComputational Imagingen_US
icr.researchteamPre-Clinical MRIen_US
dc.contributor.icrauthorZormpas Petridis, Konstantinosen
dc.contributor.icrauthorJamin, Yannen
dc.contributor.icrauthorChesler, Louisen
dc.contributor.icrauthorBlackledge, Matthewen
dc.contributor.icrauthorKoh, Dow-Muen
dc.contributor.icrauthorRobinson, Simonen
dc.contributor.icrauthorYuan, Yinyinen
dc.contributor.icrauthorPoon, Evonen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record